Search clinical trials for: Raltegravir/3TC

Total 1509 results

Southern California Institute for Research and...
Merck Sharp & Dohme LLC

Unknown

Pilot Study of Raltegravir Lipodystrophy IISP

HIV Infection

United States
Hospital Clinic of Barcelona

Unknown

Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression (RAL-dyn)

HIV Infection

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
National Center for Research Resources (NCRR)
University of Pittsburgh

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

Systemic Sclerosis | Raynaud Disease
University of North Carolina, Chapel Hill

Completed

A Key Link for Transmission Prevention (MP3)

HIV

Malawi
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
Guangzhou 8th People's Hospital
Fifth Affiliated Hospital, Sun Yat-Sen University; Dongguan People's Hospital; First Affiliated Hospital of Guangxi Medical University and other collaborators

Recruiting

Dolutegravir Plus Lamivudine Simplified Therapy

HIV/AIDS

China
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pharmacokinetics Distribution of Raltegravir by PET/MR

HIV-1-infection

United States
Lin, Hsi-Hsun, M.D.

Completed

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (TaISENWITCH)

HIV Infection | Quality of Life | Adverse Drug Reaction

Taiwan
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)

HIV-1 Infection
Vanderbilt University

Completed

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

HIV Infections

United States
Hospital Clinic of Barcelona

Unknown

Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers (RALMET-VOLHCB)

Healthy Volunteers

Spain
Hospital Clinic of Barcelona

Completed

Switching From PI to RALtegravir in HIV Stable Patients (SPIRAL)

HIV Infections

Spain
Changi General Hospital
National University Hospital, Singapore; Merck Sharp & Dohme LLC

Completed

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

Human Immunodeficiency Virus

Singapore
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation (RAPID)

HIV
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

HIV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

HIV Infections
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC; The Alfred; Holdsworth House Medical Practice

Completed

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density (TROP)

HIV Infections | HIV | Osteoporosis | Osteopenia

Australia
Pedro Cahn
Merck Sharp & Dohme LLC

Terminated

Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

HIV Infections

Argentina
Boehringer Ingelheim

Completed

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Healthy
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
The HIV Netherlands Australia Thailand Research...
Mylan Laboratories

Completed

Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz

HIV

Thailand
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

HIV

Spain
University of South Florida
Merck Sharp & Dohme LLC; St. Joseph's Hospital, Florida

Completed

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Virus Diseases | HIV

United States
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Infection, Human Immunodeficiency Virus

United States, Canada, Puerto Rico
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
University of Nebraska

Completed

Measurement of Plasma and Intracellular Concentrations of Raltegravir

HIV

United States
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (LIVERAL)

Hepatitis C | Human Immunodeficiency Virus

Spain
Catholic University of the Sacred Heart

Completed

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

HIV Infections | HIV/AIDS | Antiretroviral Therapy

Italy
University of Washington
Merck Sharp & Dohme LLC

Terminated

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (UW PIC 330)

Human Immunodeficiency Virus

United States
Hospital Carlos III, Madrid

Unknown

Simplification From Protease Inhibitors to Raltegravir (ODIS)

HIV Infections

Spain
Hospital Clinic of Barcelona

Completed

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients (RAL-LT-HIV)

Liver Transplantation | HIV Infections | Antiretroviral Therapy
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

HIV Infection

United States
Canadian Immunodeficiency Research Collaborative
National Institutes of Health (NIH)

Completed

Integrase Inhibitor (MK-0518) Viral Decay

HIV Infections

Canada
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
Guangzhou 8th People's Hospital
Wuhan Union Hospital, China; LiuZhou People's Hospital; Tianjin Second People... and other collaborators

Recruiting

Simplified Treatment of Anti-retrovirus in China (C-STAR)

HIV/AIDS

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

HIV Infections | HIV-1 Infection
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

HIV
VA Office of Research and Development

Completed

Continuing the Conversation: Using Narrative Communication to Support Hypertension Self-management in African American Veterans

Hypertension

United States
Westat
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy...

Completed

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

HIV Infections

United States, Puerto Rico, Thailand, Argentina, Brazil, South Africa, Tanzania
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC

Completed

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

Fatty Liver | HIV | Nonalcoholic Steatohepatitis

Canada
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

HIV Infections

Spain
Peking Union Medical College

Unknown

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

AIDS/HIV PROBLEM

China
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

Pregnancy | HIV | Prevention

Malawi, Zimbabwe
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Imperial College London

Completed

The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

HIV Infections

United Kingdom

3

Subscribe